RENGENERON PHARMACEUTICALS, INC.
BiotechRENGENERON PHARMACEUTICALS, INC. is a biotechnology company focused on Oncology.
FDA Novel Drug Designations
(2025)See 1 novel approval →
RENGENERON PHARMACEUTICALS, INC.'s Key Drugs
RENGENERON PHARMACEUTICALS, INC.'s core commercial portfolio centers on LYNOZYFIC, spanning Oncology — its most strategically important drugs approved in the last 15 years.
RENGENERON PHARMACEUTICALS, INC.'s Recent FDA Approvals
RENGENERON PHARMACEUTICALS, INC. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
RENGENERON PHARMACEUTICALS, INC.'s Therapeutic Areas
RENGENERON PHARMACEUTICALS, INC.'s approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RENGENERON PHARMACEUTICALS, INC.'s Top Competitors
RENGENERON PHARMACEUTICALS, INC.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RENGENERON PHARMACEUTICALS, INC. Pipeline Snapshot
Active clinical trials for RENGENERON PHARMACEUTICALS, INC. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYNOZYFIC leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-07-02
- Latest
- 2025-07-02
- Applications
- 1